UCB Inspired by patients. Driven by science. BioTrinity 2016

UCB: making lives better every day Bringing solutions to people living with neurological or immunological diseases Key facts and figures (2015): Revenue: €3.88 billion rEBITDA: €821 million More than 7500 employees globally Operations in ~40 countries R&D Spend: 27% of revenue Listed on Euronext

UCB: reinventing itself, leveraging a solid heritage 1972: A new state-of-the-art R&D center in Braine-l’Alleud, Belgium Today 2006: UCB acquires German pharma company Schwarz Pharma 1928: Emmanuel Janssen establishes UCB in Brussels 1990s: approval of Keppra®, a novel anti-epileptic Combine leadership in antibody research & chemistry expertise to better treat severe diseases 1952: UCB discovers Atarax® U.S. license awarded to Pfizer 2004: UCB acquires British biotech company Celltech Launch of Cimzia®, Vimpat® & Neupro® (CVN) 1980s: UCB registers its novel antihistamine Zyrtec® 1936: UCB enters the United States 1928 1936 1952 1972 1980s 1990s 2004 2006 2008-2010 Today Chemical Group Primary Care Pharma Specialty Bio-pharma

Growth Drivers: Core medicines tracking well towards peak sales target of € 3.1 billion* EXPECTED AT LEAST € 1.5 billion peak sales Inflammatory arthritis indications and Crohn’s disease Psoriasis: strategic collaboration with Dermira 1.2 Epilepsy Partial-Onset Seizures Monotherapy in the U.S. Partner in Japan: Daiichi Sankyo 400 million peak sales Parkinson’s disease and Restless Legs Syndrome Partner in Japan: Otsuka * By the end of this decade

Briviact® (brivaracetam) in epilepsy POS1 Epilepsy seizure reduction in treatment resistant patients Approved in Europe (Jan. 2016) and in the U.S. (Feb. 2016) Guoqiong, living with epilepsy One of the largest Phase 3 programs in epilepsy Extensive clinical data: Over 3000 patients involved in the trials; 212 non-clinical studies, 51 clinical studies Statistically significant AND clinically relevant top-line results² 1 POS: partial-onset seizures 2 The most commonly reported adverse events were somnolence, dizziness, fatigue and headache. Source: UCB data on file 3 American Epilepsy Society

A promising pipeline for differentiating solutions Phase 1 Phase 2 Phase 3 Filing romosozumab Osteoporosis bimekizumab / UCB4940 (IL17AF) Immunology indications Phase 2b start: H2 2016 bimekizumab add-on to Cimzia® rheumatoid arthritis Phase 2a results: H1 2017 UCB0942 (PPSI) highly drug resistant epilepsy Phase 2a results: Q1 2017 seletalisib (PI3K Delta inhibitor) dapirolizumab pegol (CD40L antibody) systemic lupus erythematosus Phase 2b start: Q3 2016 (Partner: Biogen) UCB7665 Phase 2 start: Q2 2016 UCB4144 / VR942 asthma (Partner: Vectura) UCB1332 / NPT200-11 Parkinson’s disease (Partner: Neuropore) UCB6673 Immunology indications (Partner: King’s College London) (Partner: Amgen) neurology immunology

Cutting-edge research and science Addressing unmet patient needs and delivering breakthrough medicines Two main Research Centers World-class expertise in selected therapeutic areas and disease mechanisms Connecting science in new ways - chemistry (small, chemically-derived molecules) and biology (large antibody-based molecules), to leverage the potential of these two disciplines ‘Open innovation’ model based on strong partnerships with other biotech companies and prominent universities Biologics pilot plant – Braine-l’Alleud, Belgium Biologics R&D centre - Slough, U.K. Two main Research Centers

UCB’s partnering strategy seeks patient solutions from discovery to commercial stage NEUROLOGY Seizure disorders (e.g. refractory epilepsy, rare genetic forms, autoimmune epilepsy, epileptogenesis) Neurodegenerative diseases (disease modification) Movement disorders (e.g. disease modifying therapies, non-dopaminergic therapies) Other diseases primarily treated by neurologists, including orphan indications IMMUNOLOGY Autoimmune disorders Inflammatory diseases Fibrosis B-cell diseases Neuro-inflammatory diseases Other diseases primarily treated by rheumatologists and other autoimmune/inflammatory disease specialists